

public conference beginning at 7 a.m. on June 11, 2013. The cost of registration is as follows:

ISPE Member .....	\$1,545 (prior to May 13); \$1,745 (after May 13 and onsite).
ISPE Nonmember .....	\$1,905 (prior to May 13); \$2,115 (after May 13 and onsite).
ISPE New Member .....	\$1,814 (prior to May 13); \$2,014 (after May 13 and onsite).
Federal Government Employee registering prior to/after May 13 .....	\$500.
FDA Planning Committee Members and Invited Speakers .....	(free) Fee Waived.
ISPE Active, Functional and Program Committee Members .....	\$1,005 (prior and after May 13).
Student (prior to/after May 13) .....	\$200.
Individuals from Academia/Emerging Economy .....	\$1,005 (prior to May 13); \$1,135 (after May 13 and onsite).

**Registration instructions:** To register, please submit your name, affiliation, mailing address, phone number, fax number, and email address, along with a check or money order payable to "ISPE." To register via the Internet, go to the ISPE Web site, [www.ISPE.org](http://www.ISPE.org), to confirm the prevailing registration fees.

Dated: May 1, 2013.

**Leslie Kux,**

*Assistant Commissioner for Policy.*

[FR Doc. 2013-10651 Filed 5-3-13; 8:45 am]

**BILLING CODE 4160-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** Center for Scientific Review Special Emphasis Panel; VH-BST Member Conflicts.

**Date:** May 21, 2013.

**Time:** 1:00 p.m. to 3:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call).

**Contact Person:** Olga A Tjurmina, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4138, MSC 7814, Bethesda, MD 20892, (301) 451-1375, [ot3d@nih.gov](mailto:ot3d@nih.gov).

This notice is being published less than 15 days prior to the meeting due to the timing

limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: April 30, 2013.

**Melanie J. Gray,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013-10570 Filed 5-3-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Clinical Trials Units for NIAID Networks.

**Date:** May 31, 2013.

**Time:** 10:00 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 1202, 6700B Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).

**Contact Person:** Roberta Binder, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, Room 3130, Bethesda, MD

20892-7616, 301-496-7966, [rbinder@niaid.nih.gov](mailto:rbinder@niaid.nih.gov).

**Name of Committee:** National Institute of Allergy and Infectious Diseases Special Emphasis Panel; Clinical Trials Unit for NIAID Networks.

**Date:** July 2, 2013.

**Time:** 10:00 a.m. to 5:00 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Institutes of Health, 3130, 6700B Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call).

**Contact Person:** Roberta Binder, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institutes of Health/NIAID, 6700B Rockledge Drive, Room 3130, Bethesda, MD 20892-7616, 301-496-7966, [rbinder@niaid.nih.gov](mailto:rbinder@niaid.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: April 30, 2013.

**David Clary,**

*Program Analyst, Office of Federal Advisory Committee Policy.*

[FR Doc. 2013-10575 Filed 5-3-13; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.